← 返回

治疗脑多形性胶质母细胞瘤的未来一代联合多模式方法及其对排尿控制的潜在影响

英文原题:Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control.

查看英文原题

Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control.

PubMed 2021/09/16(内容时间) Rev Neurosci Q1 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

即使接受标准治疗,胶质母细胞瘤仍具有致命性。本综述旨在概述胶质母细胞瘤多种先进疗法的近期进展,并简要讨论胶质母细胞瘤及部分治疗方法对排尿控制这一神经功能的潜在影响。免疫疗法虽已成功治疗血液系统恶性肿瘤,但在脑胶质母细胞瘤治疗中尚未取得类似成功。再生医学和干细胞疗法也未在胶质母细胞瘤治疗中取得显著成功。然而,CRISPR-Cas系统具备敲入和敲除基因、改造免疫细胞及细胞受体等能力,因而有望用于多种场景,并应对CAR-T 免疫疗法和脑胶质母细胞瘤再生治疗中的临床挑战,提高此类方法的精确性和安全性。本综述所述研究提示,胶质母细胞瘤是一种存在多重复杂障碍、亟待克服的恶性疾病,研究者尝试实现有效治愈时还可能遇到更多挑战。未来一代由CRISPR-Cas疗法、免疫疗法和再生疗法组成的多模式、精细化且安全的治疗策略,可能延长生存,甚至带来潜在治愈机会。

展开英文摘要原文

Glioblastoma remains lethal even when treated with standard therapy. This review aims to outline the recent development of various advanced therapeutics for glioblastoma and briefly discuss the potential impact of glioblastoma and some of its therapeutic approaches on the neurological function micturition control. Although immunotherapy led to success in treating hematological malignancies, but no similar success occurred in treatment for brain glioblastoma. Neither regenerative medicine nor stem cell therapy led to astounding success in glioblastoma.

However, CRISPR Cas system holds potential in multiple applications due to its capacity to knock-in and knock-out genes, modify immune cells and cell receptors, which will enable it to address clinical challenges in immunotherapy such as CAR-T and regenerative therapy for brain glioblastoma, improving the precision and safety of these approaches.

The studies mentioned in this review could indicate that glioblastoma is a malignant disease with multiple sophisticated barriers to be overcome and more challenges might arise in the attempt of researchers to yield a successful cure. A multimodal approach of future generation of refined and safe therapeutics derived from CRISPR Cas therapeutics, immunotherapy, and regenerative therapeutics mentioned in this review might prolong survival or even contribute towards a potential cure for glioblastoma.

论文信息

作者
Zeng XX、Zeng J、Zhu B
第一作者单位
Guangzhou United Family Hospital, Fangyuan Road 28, Haizhu District, Guangzhou, Postcode: 510000, Guangdong Province, P. R. China.China
通讯作者单位
The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Yinquan Road B24, Qingyuan City, Postcode: 511500, Guangdong Province, P. R. China.China
文献类型
综述 · 非美国政府资助研究
期刊
Reviews in the neurosciences2022 Apr 26
原文标识
PubMed 34529907 · DOI 10.1515/revneuro-2021-0068